Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000633042 | SCV000754254 | uncertain significance | Spastic paraplegia | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with tyrosine, which is neutral and polar, at codon 273 of the SACS protein (p.Phe273Tyr). This variant is present in population databases (rs182864646, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with SACS-related conditions. ClinVar contains an entry for this variant (Variation ID: 527998). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001829781 | SCV002791074 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2022-03-29 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001829781 | SCV002086748 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2019-11-11 | no assertion criteria provided | clinical testing |